Roche could top Pfizer, Lilly by 2014

While Pfizer, Eli Lilly, J&J, GlaxoSmithKline and Sanofi-Aventis face expiring patents and a sizeable drop in rank in the coming years, Roche might hold strong and is poised to carry about 6 percent of the global prescription drug market in 2014. Ranked fifth in 2007, the company is also less at risk of losing revenue to genetic competitors. Report

Suggested Articles

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…